{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:48:47Z","timestamp":1772606927779,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lpm.2022.104142","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T03:03:57Z","timestamp":1665803037000},"page":"104142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["New immunosuppressive agents in transplantation"],"prefix":"10.1016","volume":"51","author":[{"given":"Delphine","family":"Kervella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-6143.2011.03504.x","article-title":"Chronic calcineurin inhibitor nephrotoxicity-lest we forget","volume":"11","author":"Chapman","year":"2011","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0002","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/ajt.13946","article-title":"Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients","volume":"16","author":"Dugast","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0003","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0004","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney International"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"issue":"9863","key":"10.1016\/j.lpm.2022.104142_bib0006","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(12)61265-3","article-title":"Antibody-mediated vascular rejection of kidney allografts: a population-based study","volume":"381","author":"Lefaucheur","year":"2013","journal-title":"The Lancet."},{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0008","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and Long-Term Outcomes in Kidney Transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0010","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","article-title":"Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR)","volume":"19","author":"Leibler","year":"2019","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0011","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0012","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ajt.16386","article-title":"Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients","volume":"21","author":"Kirk","year":"2021","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.lpm.2022.104142_bib0013","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0014","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/01.TP.0000121761.02129.A6","article-title":"FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation","volume":"79","author":"Tedesco-Silva","year":"2005","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0015","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","article-title":"FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia","volume":"6","author":"Salvadori","year":"2006","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0016","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/01.tp.0000251718.95622.b3","article-title":"Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation","volume":"82","author":"Tedesco-Silva","year":"2006","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0017","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1093\/ndt\/gfr503","article-title":"on behalf of the FTY720 Phase II Transplant Study Group. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study","volume":"26","author":"Hoitsma","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0018","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0020","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/ajt.12303","article-title":"Alefacept Combined With Tacrolimus, Mycophenolate Mofetil and Steroids in De Novo Kidney Transplantation: A Randomized Controlled Trial","volume":"13","author":"Rostaing","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"5646","key":"10.1016\/j.lpm.2022.104142_bib0021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0022","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients","volume":"9","author":"Busque","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1016\/j.lpm.2022.104142_bib0023","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year","volume":"12","author":"Vincenti","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0024","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1016\/j.lpm.2022.104142_bib0025","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1097\/TXD.0000000000000819","article-title":"Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial","volume":"4","author":"Busque","year":"2018","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0026","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0027","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0028","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/ajt.12255","article-title":"Sotrastaurin in Calcineurin Inhibitor\u2013Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients","volume":"13","author":"Tedesco-Silva","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0029","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/ajt.12251","article-title":"Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results","volume":"13","author":"Russ","year":"2013","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0030","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/ajt.13175","article-title":"Protein Kinase C Inhibitor Sotrastaurin in De Novo Liver Transplant Recipients: A Randomized Phase II Trial","volume":"15","author":"Pascher","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.lpm.2022.104142_bib0032","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.4049\/jimmunol.154.10.4996","article-title":"The CD40 ligand expressed by human B cells costimulates B cell responses","volume":"154","author":"Grammer","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2022.104142_bib0033","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-0-387-70630-6_11","article-title":"TRAF proteins in CD40 signaling","volume":"597","author":"Bishop","year":"2007","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0034","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.178.5.1567","article-title":"In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39","volume":"178","author":"Foy","year":"1993","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.180.1.157","article-title":"gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory","volume":"180","author":"Foy","year":"1994","journal-title":"Journal of Experimental Medicine"},{"issue":"6412","key":"10.1016\/j.lpm.2022.104142_bib0036","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/361541a0","article-title":"Saint Basile G de. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM","volume":"361","author":"DiSanto","year":"1993","journal-title":"Nature"},{"issue":"5283","key":"10.1016\/j.lpm.2022.104142_bib0037","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1126\/science.273.5283.1862","article-title":"CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40","volume":"273","author":"Yang","year":"1996","journal-title":"Science"},{"issue":"6581","key":"10.1016\/j.lpm.2022.104142_bib0038","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/381434a0","article-title":"Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways","volume":"381","author":"Larsen","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2022.104142_bib0039","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/9536","article-title":"Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates","volume":"5","author":"Kirk","year":"1999","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0041","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.TP.0000116563.72763.83","article-title":"Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation1","volume":"77","author":"Schuler","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0042","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000116392.72152.75","article-title":"Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model","volume":"77","author":"Kanmaz","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"issue":"6667","key":"10.1016\/j.lpm.2022.104142_bib0044","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0045","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/ajt.14197","article-title":"Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection","volume":"17","author":"Kim","year":"2017","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0046","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.tp.0000286058.79448.c7","article-title":"A Novel Fully Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys","volume":"84","author":"Imai","year":"2007","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0047","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1600-6143.2009.02693.x","article-title":"A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy","volume":"9","author":"Aoyagi","year":"2009","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0048","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0000000000000236","article-title":"Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys","volume":"98","author":"Song","year":"2014","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0049","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/j.1600-6143.2012.04014.x","article-title":"Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates","volume":"12","author":"Oura","year":"2012","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0050","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ajt.12678","article-title":"Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects","volume":"14","author":"Okimura","year":"2014","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0051","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ajt.15560","article-title":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","volume":"20","author":"Vincenti","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0052","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0053","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/ajt.13377","article-title":"A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion","volume":"15","author":"Cordoba","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0054","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-065X.1998.tb01246.x","article-title":"Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy","volume":"165","author":"Powell","year":"1998","journal-title":"Immunological Reviews"},{"issue":"5899","key":"10.1016\/j.lpm.2022.104142_bib0056","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.lpm.2022.104142_bib0057","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(07)95004-X","article-title":"Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies","volume":"95","author":"H\u00fcnig","year":"2007","journal-title":"Adv Immunol"},{"key":"10.1016\/j.lpm.2022.104142_bib0058","first-page":"11","article-title":"Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412","author":"Suntharalingam","year":"2006","journal-title":"n engl j med"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0059","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/TP.0b013e31816846f6","article-title":"A Blocking Anti-CD28-Specific Antibody Induces Long-Term Heart Allograft Survival by Suppression of the PKC\u03b8-JNK Signal Pathway","volume":"85","author":"Jang","year":"2008","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4161\/mabs.22697","article-title":"Antagonist properties of monoclonal antibodies targeting human CD28","volume":"5","author":"Mary","year":"2013","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.lpm.2022.104142_bib0061","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1111\/j.1600-6143.2012.04164.x","article-title":"Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab\u2032 Antibody","volume":"12","author":"Poirier","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0062","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2002-08-2480","article-title":"Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody","volume":"102","author":"Vanhove","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0063","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4161\/mabs.28375","article-title":"Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28","volume":"6","author":"Poirier","year":"2014","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0064","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","article-title":"First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28","volume":"197","author":"Poirier","year":"2016","journal-title":"The Journal of Immunology"},{"issue":"19","key":"10.1016\/j.lpm.2022.104142_bib0065","doi-asserted-by":"crossref","first-page":"89381","DOI":"10.1172\/jci.insight.89381","article-title":"Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses","volume":"2","author":"Zaitsu","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0066","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ajt.12964","article-title":"FR104, an Antagonist Anti-CD28 Monovalent Fab\u2019 Antibody, Prevents Alloimmunization and Allows Calcineurin Inhibitor Minimization in Nonhuman Primate Renal Allograft","volume":"15","author":"Poirier","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0067","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1681\/ASN.2015070774","article-title":"Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection","volume":"27","author":"Ville","year":"2016","journal-title":"JASN"},{"issue":"9","key":"10.1016\/j.lpm.2022.104142_bib0068","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.4049\/jimmunol.1300470","article-title":"A Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety","volume":"191","author":"Suchard","year":"2013","journal-title":"The Journal of Immunology"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0069","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jcph.791","article-title":"Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects","volume":"57","author":"Shi","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0070","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"JASN"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0071","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0072","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0073","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-Mediated Rejection of Solid-Organ Allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0074","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.lpm.2022.104142_bib0075","doi-asserted-by":"crossref","unstructured":"Gelfand EW. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. https:\/\/doi.org.proxy.insermbiblio.inist.fr\/10.1056\/NEJMra1009433. doi:10.1056\/NEJMra1009433","DOI":"10.1056\/NEJMra1009433"},{"issue":"9","key":"10.1016\/j.lpm.2022.104142_bib0076","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.TP.0000060252.57111.AC","article-title":"Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection","volume":"75","author":"Rocha","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0077","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0078","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0079","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"JASN"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0081","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0082","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post\u2013kidney Transplantation: A Consecutive Series of 15 Cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0083","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year","volume":"15","author":"Cornell","year":"2015","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0084","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies","volume":"19","author":"Schinstock","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0085","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study","volume":"16","author":"Montgomery","year":"2016","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0086","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.lpm.2022.104142_bib0087","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/TP.0000000000003249","article-title":"Interleukin-6: An Important Mediator of Allograft Injury","volume":"104","author":"Jordan","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0088","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007890-199103000-00012","article-title":"Differential in situ expression of cytokines in renal allograft rejection","volume":"51","author":"Vandenbroecke","year":"1991","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.lpm.2022.104142_bib0089","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","article-title":"Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction","volume":"63","author":"Casiraghi","year":"1997","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0090","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ajt.13644","article-title":"HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion","volume":"16","author":"Lion","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.lpm.2022.104142_bib0091","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of Tocilizumab (Anti\u2013Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients","volume":"17","author":"Choi","year":"2017","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0092","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/ctr.13908","article-title":"Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation","volume":"34","author":"Lavacca","year":"2020","journal-title":"Clinical Transplantation"},{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0093","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/ajt.16391","article-title":"Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?","volume":"21","author":"Massat","year":"2021","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0094","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A Randomized Clinical Trial of Anti\u2013IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection","volume":"32","author":"Doberer","year":"2021","journal-title":"JASN"},{"issue":"8","key":"10.1016\/j.lpm.2022.104142_bib0095","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1097\/TP.0000000000003512","article-title":"Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients","volume":"105","author":"Sethi","year":"2021","journal-title":"Transplantation"},{"issue":"14","key":"10.1016\/j.lpm.2022.104142_bib0096","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lpm.2022.104142_bib0097","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104142_bib0098","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0099","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003505","article-title":"Daratumumab for Antibody-mediated Rejection in Heart Transplant\u2014A Novel Therapy: Successful Treatment of Antibody-mediated Rejection","volume":"105","author":"Aguilera Agudo","year":"2021","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.lpm.2022.104142_bib0100","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.15881","article-title":"Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients","volume":"20","author":"Jain","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0101","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.lpm.2022.104142_bib0102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.kint.2020.08.020","article-title":"Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model","volume":"99","author":"Schroder","year":"2021","journal-title":"Kidney International"},{"issue":"3","key":"10.1016\/j.lpm.2022.104142_bib0103","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney International"},{"issue":"6","key":"10.1016\/j.lpm.2022.104142_bib0104","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1016\/j.lpm.2022.104142_bib0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"11","key":"10.1016\/j.lpm.2022.104142_bib0106","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.lpm.2022.104142_bib0107","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/j.1600-6143.2012.04194.x","article-title":"BAFF and BAFF-R Levels Are Associated With Risk of Long-Term Kidney Graft Dysfunction and Development of Donor-Specific Antibodies","volume":"12","author":"Thibault-Espitia","year":"2012","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1016\/j.lpm.2022.104142_bib0108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e318298dd65","article-title":"Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection","volume":"96","author":"Banham","year":"2013","journal-title":"Transplantation"},{"issue":"10140","key":"10.1016\/j.lpm.2022.104142_bib0109","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/S0140-6736(18)30984-X","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"The Lancet"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:53Z","timestamp":1760105333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498222000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0755498222000355"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104142","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New immunosuppressive agents in transplantation","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104142"}}